ClinicalTrials.gg
CompletedNCT01290367Updated Jun 26, 2020

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

A Phase 2 interventional study of Single Dose MPCs Injection and Single injection of saline solution in Degenerative Disc Disease, sponsored by Mesoblast, Ltd.. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-26.

Sponsored by Mesoblast, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 60 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
47th of 141
100 · median 57
Started
2011
with 7 others
Phase 2
10 of 232
none open now
Registered
56th of 232
by date
Lead sponsor
6 of 232
Mesoblast, Ltd.

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 47th largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2011, is one of 10 in phase 2, and was the 56th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare two doses of immunoselected, culture-expanded, nucleated, allogeneic adult MPCs when combined with hyaluronic acid to two control intradiscal injections in subjects with chronic low back pain due to moderate Degenerative Disc Disease (DDD) at one lumbar level from L1 to S1.

All investigational subjects in this study will undergo injection of either 6 million (M) or 18M cells in a hyaluronic acid carrier into the degenerated lumbar disc's nucleus pulposus. All control subjects will undergo an intradiscal control injection with either saline or hyaluronic acid only

Read the detailed description

This is a prospective, multicenter, double blinded, controlled clinical study comparing two doses of immunoselected, culture-expanded, nucleated, allogeneic adult MPCs when combined with hyaluronic acid to two control intradiscal injections in subjects with chronic low back pain (> 6 months) due to moderate DDD at one lumbar level from L1 to S1 and unresponsive to conservative therapy for at least 3 months (including physical therapy).

After the screening and injection visits, each subject will be evaluated clinically and radiographically at 30 days, and again at 3, 6, 12, 24 and 36 months after injection.

Subjects will be evaluated at the same time points for safety.

03

Conditions studied

  • Degenerative Disc Disease

Keywords

  • Chronic Lumbar Back Pain
  • Low back pain
  • Back pain
  • Degenerative Disc Disease
  • Injection of Degenerated Lumbar Disc
  • Stem Cells
  • Adult Stem Cells
  • Allogeneic Mesenchymal Precursor cells (MPCs)
  • Mesoblast
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or females at least 18 years of age.
  2. Have the ability to understand the requirements of the study, to provide written , and to comply with the study protocol.
  3. Have the ability to understand and provide written authorization for the use and disclosure of personal health information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) privacy ruling in the US].
  4. Have chronic low back pain for at least 6 months.
  5. Have documented symptomatic diagnosis of DDD of one level from L1-S1 as determined by a change in disc hydration on MRI compared to normal disc with or without an annular fissure or a contained disc herniation.
  6. Have failed 3 months of non-operative low back pain management.
  7. Disc height loss of \<30% compared to a normal adjacent disc based upon radiographic evaluation.
  8. Pre-treatment baseline low back pain of at least 40 mm on a 100 mm visual analog scale.
  9. Low back pain greater than leg pain.
  10. Pre-treatment baseline Oswestry Disability Index Questionnaire score of at least 30 on the 100-point questionnaire.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or nursing, or women planning to become pregnant during the first year (12 months) following surgery.
  2. Have a current or prior history within the last 3 years of neoplasm (excluding basal cell carcinoma) and/or any active neoplasm within the last 24 months, prior to screening.
  3. Patients with compressive pathology due to stenosis or frankly herniated disc or sequestered discs are not candidates.
  4. Intact disc bulge/protrusion or focal herniation at the symptomatic level (s) > 3 mm or presence of disc extrusion or sequestration.
  5. Lumbar spondylitis or other undifferentiated spondyloarthropathy.
  6. Have undergone a previous surgery at the involved levels.
  7. Any lumbar intradiscal injection procedure (e.g., injection of , methylene blue, dextrose, or glucosamine and chondroitin sulfate). Discography may be performed, but must be done at least 2 weeks or more prior to the MPC injection procedure.
  8. Have an acute fracture of the spine at the time of enrollment in the study.
  9. Have a history of epidural steroid injections within 1 week prior to study treatment.
  10. Have a known history of or anaphylactic reaction to murine or bovine products or dimethyl sulfoxide (DMSO).
  11. Have a positive screen for (HIV) antibodies.
  12. Have a known history of hypersensitivity or anaphylactic reaction to Hyaluronan.
  13. Have a current or prior history within the last 3 years of neoplasm (excluding basal cell carcinoma) and/or any active neoplasm within the last 24 months, prior to screening.
  14. Have been a recipient of prior stem cell/progenitor cell therapy or other biological intervention to repair the target intervertebral disc.
  15. Are transient or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an inpatient substance abuse program.
  16. Currently incarcerated (prisoners).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    High Dose MPCs

    Injection of High Dose MPCs with Hyaluronic Acid

    Biological: Single Dose MPCs Injection

  • Experimental
    Low Dose MPCs

    Injection of Low Dose MPCs with Hyaluronic Acid

    Biological: Single Dose MPCs Injection

  • Sham comparator
    Saline injection

    Injection of saline solution.

    Procedure: Single injection of saline solution

  • Placebo comparator
    Hyaluronic acid injection

    Injection of hyaluronic acid solution

    Procedure: Single injection of hyaluronic acid

Interventions

  • Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.

    Also known as: Direct MPCs Lumbar Disc Injection., Stem Cells

  • ProcedureSingle injection of saline solution

    Intradiscal control injection with saline solution

    Also known as: Saline injection, Sham control

  • ProcedureSingle injection of hyaluronic acid

    Intradiscal control injection with hyaluronic acid

    Also known as: Hyaluronic acid injection, Vehicle control

  • Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.

    Also known as: Stem Cells

06

What researchers measure

Primary outcomes

  1. To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).

    Time frame: 3 years

Secondary outcomes

  1. To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs.

    Time frame: 6 - 36 Months

  2. To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS).

    Time frame: 1 - 36 Months

07

Study locations

14 sites
  • Arizona Pain Specialists
    Scottsdale, Arizona 85258, United States
  • UC Davis Spine Center
    Sacramento, California 95816, United States
  • The Spine Institute
    Santa Monica, California 90403, United States
  • IPM Medical Group, Inc.
    Walnut Creek, California 94598, United States
  • Denver Spine
    Denver, Colorado 80111, United States
  • Rocky Mountain Associates in Orthopedic Medicine, P.C.
    Loveland, Colorado 80538, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30329, United States
  • Carolina Neurosurgery and Spine Associates
    Charlotte, North Carolina 28204, United States
  • Central Texas Spine Institute
    Austin, Texas 78731, United States
  • Richmond Bone and Joint Clinic, Memorial Hermann Medical Group
    Richmond, Texas 77469, United States
  • Virginia Spine Research Institute, Inc.
    Richmond, Virginia 23235, United States
  • Washington Center for Pain Management
    Edmonds, Washington 98026, United States
  • The Center for Pain Relief, Inc.
    Charleston, West Virginia 25301, United States
  • Monash Medical Center
    Clayton, Victoria 3168, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jul 2013 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2011
First posted
Feb 7, 2011
Start
Aug 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2015
Last update
Jun 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01290367
Lead sponsor
Mesoblast, Ltd.
Responsible party
Sponsor
First posted
Feb 7, 2011
Start date
Aug 2011
Primary completion
Jul 2013
Completion
Jul 2015
Last update
Jun 26, 2020

Study contacts

Roger Brown
study director · Mesoblast, Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion